Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies - 16/06/21
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Background |
Ruxolitinib (RUX) cream demonstrated potent anti-inflammatory and antipruritic efficacy in a phase 2 study in adults with atopic dermatitis (AD).
Objective |
To evaluate 8-week efficacy and safety in 2 phase 3 studies of RUX cream in patients with AD.
Methods |
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (NCT03745638) and Study 2 (NCT03745651) enrolled patients aged ≥12 years with AD for ≥2 years, an Investigator's Global Assessment score of 2/3, and 3%-20% affected body surface area. Patients were randomized 2:2:1 to twice-daily 0.75% RUX cream, 1.5% RUX cream, or vehicle cream for 8 continuous weeks. The primary endpoint was Investigator's Global Assessment treatment success at week 8 (Investigator's Global Assessment score of 0/1 and ≥2-grade improvement from baseline).
Results |
In the Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 and 2, 631 and 618 patients were randomized (631/577 analyzed for efficacy). Significantly more patients achieved Investigator's Global Assessment treatment success with 0.75% RUX cream (50.0%/39.0%) and 1.5% RUX cream (53.8%/51.3%) versus vehicle (15.1%/7.6%; P < .0001) at week 8. Significant itch reductions versus vehicle were reported within 12 hours of first application of 1.5% RUX (P < .05). Application site reactions were infrequent (<1%) and lower with RUX versus vehicle; none were clinically significant.
Limitations |
Longer-term safety data are not yet available.
Conclusions |
RUX cream showed anti-inflammatory and prompt antipruritic effects with superior efficacy versus vehicle and was well tolerated.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, itch, JAK inhibitor, Janus kinase, ruxolitinib, topical
Abbreviations used : AD, AE, BSA, EASI, EASI-75, EASI-90, IC50, IGA, IGA-TS, JAK, NRS, NRS4, QoL, RUX, TEAE, TRuE-AD1, TRuE-AD2, VC, WB
Plan
Funding sources: Funding was provided by Incyte Corporation. |
|
IRB approval status: The study protocol was approved by each site's institutional review board. |
|
Reprints not available from the authors. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?